Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: A systematic review and meta-analysis

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: Causal modeling, timing, and classes of concomitant medications

13 p | 11 | 3

Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors

8 p | 7 | 3

LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: A retrospective study

11 p | 3 | 2

Re-challenging immune checkpoint inhibitor in a patient with advanced nonsmall cell lung cancer: A case report

4 p | 7 | 2

Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: A Korean, multicenter study (KCSG ST22-06)

12 p | 1 | 1

Response to immune checkpoint inhibitor combination therapy in metastatic RETmutated lung cancer from real-world retrospective data

9 p | 2 | 1

Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: A retrospective multicenter study

9 p | 1 | 1

Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: A multicenter, real-world retrospective study in China

8 p | 2 | 1

Checkpoint inhibitors in metastatic gastric and GEJ cancer: A multi-institutional retrospective analysis of real-world data in a Western cohort

10 p | 16 | 0